Precipio, Inc. (PRPO)

Precipio's stock has been impacted by several events over the past six months. Strong Q3 2025 financial performance led to an 8.8% increase in shares. The company showcased its BCR::ABL1 panel at the ASH Meeting. A cybersecurity incident was disclosed with no operational impact. The company announced steps towards a clean balance sheet, including debt repayment and warrant exercises. Precipio terminated its ATM facility due to an improved financial position. The stock price saw a substantial increase of 253.67% from February 3, 2025, to February 2, 2026, but has recently declined.

Precipio, Inc. experiences demand seasonality for its products and services. The company reported anticipated slower seasonal revenues in pathology and temporary delays in customer onboarding in Q1 2025, contributing to a 9.5% decline in revenues from Q4 2024 to Q1 2025. Management also anticipated a decline in cash receipts in Q1 due to seasonal delays typical in the industry.

Precipio, Inc. is a healthcare solutions company specializing in cancer diagnostics, focusing on addressing cancer misdiagnoses through diagnostic products, reagents, and services. Its major products and technologies include HemeScreen, IV-Cell, and ICE-COLD-PCR (ICP). Precipio also operates CLIA laboratories providing blood cancer diagnostics and pathology services.

Precipio, Inc. has operational and R&D facilities in New Haven, Connecticut, and Omaha, Nebraska. It provides blood cancer diagnostics nationwide through its CLIA laboratories. Its IV-Cell media has been accepted by a Japanese laboratory, indicating a global reach.

Precipio's brand reputation has been positively influenced by scientific advancements and collaborations. The company builds credibility through scientific presentations and joint clinical studies. The acceptance of Precipio's IV-Cell media by a premier Japanese laboratory strengthens its international standing. A cybersecurity incident was disclosed, but the company stated that there was no operational impact.

Precipio, Inc.'s ownership is distributed among institutional and individual investors. Approximately 14.50% to 15.48% of the company's stock is held by institutional investors, while insiders own about 11.21%. Major institutional owners include AMH Equity Ltd, Topline Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc.